Evidence mapPaperPMID 41893357Full record

ArticleMetabolites2026

Metformin Regulation of the Liver Circadian Clock and Metabolic Aging: A Systems Modeling Study.

Mengyuan Zhang, Ying Li

Abstract read
In one paragraph

Article in Metabolites, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mengyuan ZhangCollege of Information Technology, Shanghai Ocean University, Shanghai 201306, China.
Ying LiCollege of Information Technology, Shanghai Ocean University, Shanghai 201306, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAging affects both metabolic and circadian systems, leading to disruptions in energy homeostasis and phase shifts in the circadian clock. Metformin, a widely used antihyperglycemic drug, exerts anti-aging effects by modulating key pathways in the liver and also influences the liver circadian clock. However, the optimal medication strategy, including dosage and timing, that achieves significant anti-aging effects while minimizing negative impacts on the circadian clock remains unclear. This study aims to identify a rational metformin administration strategy considering both aspects.

methodsAn extended mathematical model of the liver circadian clock incorporating metformin regulation was developed, and numerical simulations were performed to evaluate different dosing times and feeding conditions.

resultsMetformin administration at different times produced distinct effects on both the circadian clock and anti-aging outcomes. Administration during the increasing phase of CLOCK-BMAL1 concentration showed positive effects on the circadian clock and effective anti-aging properties. Regarding feeding patterns, a fed-like state was not conducive to anti-aging, whereas fasting was beneficial.

conclusionsThese findings highlight the importance of dosing time and feeding styles in optimizing metformin efficacy and provide insights into its potential pharmacological applications in anti-aging therapy.

Indexed as

anti-agingliver circadian clockmathematical modelmetformin

Identifiers

PMID41893357
PMCPMC13027763

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.